Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 8Melanoma 2Sarcoma, Kaposi 1Neoplasm Metastasis 1Mycosis Fungoides 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Breast Neoplasms 1

Interventions

Doxorubicin 18Ifosfamide 13Radiotherapy 8Paclitaxel 7pazopanib 6pembrolizumab 4Gemcitabine 4Filgrastim 4Chemotherapy, Adjuvant 4Bevacizumab 4spartalizumab 3durvalumab 3Sorafenib 3Propranolol 3Nivolumab 3Ipilimumab 3Imatinib Mesylate 3Etoposide 3Epirubicin 3Docetaxel 3Carboplatin 3trebananib 2regorafenib 2cixutumumab 2cemiplimab 2carotuximab 2brostallicin 2belinostat 2balstilimab 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hemangiosarcoma × talimogene laherparepvec × Sarcoma × Clear all
NCT03921073 2022-11-01

Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
5 enrolled 5 charts
Sarcoma

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡